Aug 28, 2016
Exact Imaging touts ExactVu clinical results

July 28, 2016 -- Canadian microultrasound technology developer Exact Imaging is highlighting initial clinical results published in the Journal of Urology for its prostate risk identification microultrasound (PRI-MUS) protocol with its ExactVu platform.

The study, led by Dr. Sangeet Ghai at Princess Margaret Cancer Centre in Toronto, found that the protocol helped detect significant disease using microultrasound for real-time visualization of suspicious lesions and to guide biopsies (J Urol, August 2016, Vol. 196:2, pp. 562-569).

Exact Imaging plans to seek CE Mark approval and clearance from the U.S. Food and Drug Administration (FDA) for ExactVu in the coming months, the company said.

More News

© 2024 Exact imaging
ExactVu™, Exact Imaging™, PRI-MUS™, FusionVu™, Cognitive Assist™ and ExactVu Micro Doppler™ are trademarks of Exact Imaging.
ExactVu™ micro-ultrasound system is available for sale in the European Union (CE Mark), the United States (FDA 510(k) clearance), and in Canada (Health Canada license).